立方製藥(003020.SZ):立方藥業擬獲華潤潤曜增資、公司持其股權將降至49%
格隆匯3月2日丨立方製藥(003020.SZ)公佈,華潤潤曜擬以現金方式向上市公司子公司立方藥業增資,以1.13億元的價格認繳立方藥業新增註冊資本7258.65萬元。增資完成後,華潤潤曜持有立方藥業51%的股權,上市公司持有立方藥業49%股權,構成上市公司的資產出售。
此次交易前,立方藥業已減資至6974萬元,此次交易標的不含截至2022年9月30日經審計的未分配利潤。
此次交易前,立方藥業為上市公司全資子公司,此次交易完成後,上市公司持有立方藥業49%股權,立方藥業不再納入上市公司合併財務報表範圍。
立方藥業所處的行業為醫藥批發行業,主營業務為藥品、醫療器械、保健品等產品的批發配送。近年來,醫藥流通行業頭部效應明顯,國藥控股、華潤醫藥及上藥控股等全國大型藥品流通企業的市場份額不斷擴大,行業競爭較為激烈,且需要鉅額資金的不斷投入。因此上市公司結合自身特點和戰略規劃,擬通過此次醫藥批發資產控制權出售,集中優勢資源聚焦醫藥製造業,打造核心技術平台,並推進公司高技術壁壘產品仿創結合轉型,構築立方製藥差異化市場競爭力。同時,公司通過出售立方藥業控制權將進一步降低資產負債率,改善公司經營性現金流,提高股東投資回報,進一步提升經營質量和運營效率。
此次交易完成後,上市公司將退出醫藥商業板塊中第三方產品的分銷配送業務,並保留上市公司原有的醫藥產品的研發、生產、銷售和醫藥零售業務。此次交易完成後,上市公司仍能保持業務完整性,此次交易不會導致上市公司主要資產為現金或者無具體經營業務的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.